Cracking the code: Exhibit digs into history of encryption
Cipher | Decipher is a travelling exhibit now at the Naval Museum of Alberta. It includes an authentic Engima machine from the Second World War. Organizers say the exhibit teaches visitors how encryption has been used from war time to the present day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Canadian safety institute announces research projects as global focus shifts to AI adoption
Innovation, Science and Industry Minister Francois-Philippe Champagne, right, and founder and scientific director of MILA-Quebec Artificial Intelligence Institute Yoshua Bengio answer media questions following the launch the Canadian Artificial Intelligence Safety Institute in Montreal on Tuesday, Nov. 12, 2024. THE CANADIAN PRESS/Christinne Muschi OTTAWA — The Canadian Artificial Intelligence Safety Institute will fund research projects focusing on misinformation, generative AI and the safety of autonomous systems. It says the initial 10 projects will receive $100,000 each from its research program. They include an initiative led by AI pioneer Yoshua Bengio that will look at the hidden reasons driving decisions by large language models, a type of generative AI focused on text. The Canadian AI Safety Institute was launched last year, part of a global network of publicly backed safety institutes that emerged following a wave of calls from experts for AI regulation. But there has been a global shift towards focusing on AI adoption over safety initiatives in recent months. In Canada, the Liberal government plans to prioritize AI's economic potential as it hosts the upcoming G7 summit, and new AI minister Evan Solomon has said nothing so far about his job description. Article by Anja Karadeglija.
CTV News
6 hours ago
- CTV News
Invisible smoke from Canadian wildfires detected over Europe: study
An orange-coloured haze, resulting from a nearby wildfire, is seen on a helipad in La Ronge, Sask., in an undated handout photo. THE CANADIAN PRESS/HO-Saskatchewan Public Safety Agency Invisible smoke from Canadian wildfires has been detected high above Europe. According to a new study from the Leibniz Institute for Tropospheric Research in Germany, layers of invisible smoke were detected in Europe's atmosphere during the 2023 wildfire season. Similar results were observed again in early June. 'This suggests that the atmosphere over Europe might be more polluted than previously thought, especially during the summer wildfire season,' the study explained. Published in the journal Atmospheric Chemistry and Physics, the study was based on lidar measurements in Leibniz, Germany. Short for Light Detection and Ranging, lidar is a remote sensing technology that uses laser light to create three-dimensional models. It works similarly to radar, which uses radio waves. Lidar was able to reveal layers of wildfire smoke that were otherwise invisible on satellite images. 'In the spring and summer of 2023, huge wildfires raged across Canada, with unusual intensity in the provinces of Alberta and British Columbia,' the study said. 'With the prevailing westerly winds, large amounts of biomass-burning aerosol were transported towards Europe.' Researchers say these thin layers of smoke in the atmosphere can contribute to ice cloud formation, impacting sunlight and climate on the ground.
National Post
7 hours ago
- National Post
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. Article content Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. Article content 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Article content Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. Article content 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' Article content About Innospera Pharma Article content Article content Article content
